Tag: advanced uterine cancer options

Home / advanced uterine cancer options

Categories

Dostarlimab-gxly with chemotherapy is approved by the FDA for endometrial cancer

August 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline), followed by dostarlimab-gxly as a single agent, was approved by the Food and Drug Administration for the treatment of primary advanced or re...
advanced-uterine-cancer-options

Scan the code